52,799 Shares in Abbott Laboratories $ABT Acquired by Northcape Wealth Management LLC

Northcape Wealth Management LLC acquired a new stake in Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 52,799 shares of the healthcare product maker’s stock, valued at approximately $4,791,000. Abbott Laboratories comprises about 1.3% of Northcape Wealth Management LLC’s investment portfolio, making the stock its 23rd largest holding.

Several other institutional investors have also modified their holdings of ABT. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Abbott Laboratories Stock Up 0.9%

Shares of Abbott Laboratories stock opened at $112.63 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a market cap of $194.89 billion, a P/E ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a fifty day moving average of $102.61 and a two-hundred day moving average of $100.22.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analyst Upgrades and Downgrades

ABT has been the subject of several research analyst reports. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. TD Cowen increased their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a report on Thursday, August 13th. Finally, UBS Group dropped their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.